Abstract:Abstract Some tumors, including BC tumors, are poorly responsive or develop resistance to therapy, which creates an impetus to identify novel strategies that potentiate immunotherapy in unresponsive cancers. Vaccines against human BC have shown only limited success for prevention of BC, with the exception of yellow fever vaccine 17D (YFV), which is closely homologous to HERV-K. In order to check immune response in animal models, murine mammary tumor cells (4T1) or melanoma cells (B16F10) were employed to express a full-length HERV-K Env protein obtained from a BC patient with invasive ductal carcinoma (IDC) by stably transfecting with pLVXKenv [full-length HERV-K env, expressing extracellular surface (SU) and transmembrane (TM) domains] or pLVX vector (control). To determine whether the SU or TM has cancer-preventive effects when dosed as an HERV-K antigen vaccine, C57BL/6 female mice were immunized with cyclic dinucleotides (CDN:15 µg) and HERV-K SU (KSU), TM [harboring the HERV-K immunosuppressive domain (ISD)], or GST protein (25 µg) on day 1 and boosted on days 14 and 28. Mice were challenged with B16F10pLVX or B16F10pLVXKenv (3 X 105 cells) 18 days after the last boost of immunization. The effect of tumor challenge on tumor growth and weight was compared. Increased weight of pLVXKenv relative to pLVX control cells was observed in mice immunized with GST (2-fold increased weight). In contrast, we observed reduced weight of pLVXKenv relative to pLVX tumors in mice immunized with KSU (50% reduced weight), showing the protective effect of KSU vaccination. This protective effect disappeared in mice immunized with the TM (1.65-fold increased tumor weight), indicating that the ISD of TM may prevent an immune response to the vaccine. Increased anti-HERV-K antibody titers were demonstrated in mice immunized with KSU than with KTM. Significantly increased anti-KSU antibody titers were demonstrated in mice immunized with KSU than with GST. Interestingly, significantly increased anti-KTM antibody titers were demonstrated in mice inoculated with pLVXKenv than with pLVX. Lower percentages of CD3+CD4+, CD3+CD8+, and CD3-NK T cells from tumor tissues were observed in mice immunized with TM or SU protein and challenged with B16F10Kenv cells. Significantly increased proliferation of CD4 or CD8 T cells was demonstrated in mice immunized with KSU protein and challenged with B16F10Kenv cells than after challenge with B16F10pLVX cells. In contrast, significantly decreased proliferation of CD4 and CD8 T cells was demonstrated in mice immunized with TM and challenged with B16F10Kenv cells than with B16F10pLVX cells, reflecting immunosuppression induced by the TM vaccine. In conclusion, HERV-K SU protein, but not TM protein, can be used for cancer prevention and immunotherapy for HERV-K positive cancers. Also, TM blockade may reduce immunosuppression. Citation Format: Feng Wang-Johanning, Jia Li, Ming Li, Gary L. Johanning, Albert Lee, Tianhe Huang. Human endogenous retrovirus type K (HERV-K) env protein as a vaccine target for HERV-K+ cancer prevention [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1257.

Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice

Abstract 1257: Human Endogenous Retrovirus Type K (HERV-K) Env Protein As a Vaccine Target for HERV-K+ Cancer Prevention

Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy

Abstract 4092: Characterizing the endogenous retroviral envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine

A Novel Approach for Cancer Immunotherapy: Tumor Cells with Anchored Superantigen SEA Generate Effective Antitumor Immunity

Abstract LB340: Harnessing the gp70 endogenous retrovirus envelope protein as a universal tumor antigen for T cell therapy in mice

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice

Immunotherapy Of Tumors With Protein Vaccine Based On Chicken Homologous Tie-2

Active Immunotherapy of Tumors with a Recombinant Xenogeneic Endoglin As a Model Antigen.

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.

Active Immunotherapy Combined with Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice

Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells

Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer

The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma

Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.

Long-Term Antitumor CD8+ T Cell Immunity Induced by Endogenously Engineered Extracellular Vesicles

Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine

Antigen-specific Bacterial Vaccine Combined with Anti-Pd-l1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer.

Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice

T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer.